This filing is a pipeline-progress update with no new clinical data, no new regulatory decision, and no new financing — it functions as a routine narrative update. For a $7M micro-cap with binary IND risk, the next material catalyst is the actual IND submission outcome in Q3 2026. Traders should watch for the IND filing and FDA acceptance/refusal rather than react to today's no-news milestone recap.
Price Chart
Executive Summary
Ernexa Therapeutics provided a pre-IND progress update on ERNA-101, its lead iMSC therapy for immunologically cold tumors. The press release highlights completion of GMP manufacturing transfer, planned Q3 2026 IND submission, and Q4 2026 Phase 1 start in platinum-resistant ovarian cancer — but contains zero new clinical data, regulatory decisions, or financial results. With a $7M market cap, the stock is pricing a binary near-term catalyst: whether the IND actually clears the FDA.
Key Facts
- IND submission for ERNA-101 planned for Q3 2026; first-in-human Phase 1 expected Q4 2026
- Preclinical data (complete tumor elimination, 100% long-term survival) previously disclosed — not new
- $10.5M financing completed, providing near-term runway for 12-18 months
- Next catalyst: FDA acceptance of IND — binary outcome for $7M market-cap stock
- No new financial data, revenue, earnings, or guidance disclosed
Financial Impact
No new financial data; $10.5M financing already completed and disclosed. No revenue, EPS, or guidance reported.
Risk Factors
- IND may be rejected or placed on clinical hold by FDA, causing significant downside
- Preclinical data are old disclosures — no new in vivo or human efficacy/toxicity data presented
- Cash runway ($10.5M for 12-18 months) is thin; dilution risk remains high
- Zero analyst bullish ratings (0 Strong Buy out of 6), indicating market skepticism
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers